Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.48 |
| ▸ | C1S | P09871 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.43 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.43 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11310119 | 0.84 | MAPT (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 | |
| SCHEMBL7140438 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL3602972 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 | |
| SCHEMBL11325097 | 0.81 | MEN1 (0.57) | PIK3CDPIK3CGPIK3CAMEN1MAPT | |
| SCHEMBL3606538 | 0.80 | MAPT (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 | |
| SCHEMBL3598571 | 0.80 | MEN1 (0.52) | MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL3610837 | 0.78 | ABL1 (0.56) | C1SMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL13074374 | 0.74 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 | |
| SCHEMBL3608584 | 0.73 | PIK3CG (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 | |
| Hydrochloric Acid SCHEMBL7142142 | 0.72 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| CN-1080720-C | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| CN-1224718-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | PIK3CD 3749/4885PIK3CG 3998/4885PIK3CA 2428/4885 |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | PIK3CD 3802/4885PIK3CG 4303/4885PIK3CA 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.